安全，监管，质量和商业合规长期以来一直被视为成本中心和要求的必需品 - 但领先的组织正在认识到这些领域的创新和增长机会。本文介绍了积极主动的方法和创新对于遵守不断变化的监管要求并遵守未来至关重要。
A recent global survey of pharmaceutical CEOs shows an increase in regulatory scrutiny across many aspects of the business, including sales and marketing practices, government drug price reporting, data privacy management, and clinical operations. Changes in industry regulations are now viewed as one of the top three disruptive business trends faced by pharmaceutical and life sciences organizations, and many pharma leaders view these changes as a threat to their growth.
但是他们不必是。
长期以来，合规性一直被视为成本中心和必要性，但领先的组织正在认识到在这个领域的创新机会。